What do systematic reviews say?

CBT with therapist support vs fatigue information leaflet only

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Physical activity advice plus omega 3 vs no physical activity advice plus omega 3

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Electroacupuncture vs no treatment

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Electroacupuncture vs sham electroacupuncture

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Chemotherapy vs biological therapy

Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 0.41 [0.3, 0.57]
  1 study · 570 participants
  Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.17 [0.95, 1.44]
  4 studies · 1618 participants
  Very low

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.38 [1.2, 1.59]
  1 study · 503 participants
  Moderate

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.14 [0.95, 1.37]
  2 studies · 638 participants
  Low

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.25 [0.35, 4.51]
  1 study · 184 participants
  Low

Intervention not reported

The intervention may leads to higher serious adverse events (low certainty).

• Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax 2020 · Cochrane Headline outcomes only
  RR 12.03 [1.57, 92.3]
  1 study · 1872 participants
  Low

Intervention not reported

• Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1427 participants
  GRADE not reported

Intervention not reported

• Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 778 participants
  GRADE not reported

Intervention not reported

• Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 129 participants
  GRADE not reported

Knee replacement with tourniquet vs knee replacement without tourniquet

Knee replacement with tourniquet probably leads to higher serious adverse events compared with knee replacement without tourniquet (moderate certainty).

• Tourniquet use for knee replacement surgery 2020 · Cochrane Headline outcomes only
  RR 1.73 [1.1, 2.73]
  21 studies · 1799 participants
  Moderate

Adalimumab vs active comparators

The review found no eligible studies for this question.

• Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adalimumab vs placebo

Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).

• Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
  RR 0.56 [0.39, 0.8]
  4 studies · 1012 participants
  Moderate

Metformin vs insulin

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs meglitinides

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 112 participants
  GRADE not reported

GLP‐1 agonists vs placebo

The review found no eligible studies for this question.

• GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found